This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Mar;19(3):e126.

doi: 10.1016/S1470-2045(18)30071-8.

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

Rafael Rosell¹, Niki Karachaliou²

Affiliations

Affiliations

¹ Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² University Hospital Sagrat Cor, Quirónsalud Group, Barcelona, Spain.

PMID: 29508751
DOI: 10.1016/S1470-2045(18)30071-8

Comment

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

Rafael Rosell et al. Lancet Oncol. 2018 Mar.

. 2018 Mar;19(3):e126.

doi: 10.1016/S1470-2045(18)30071-8.

Authors

Rafael Rosell¹, Niki Karachaliou²

Affiliations

¹ Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² University Hospital Sagrat Cor, Quirónsalud Group, Barcelona, Spain.

PMID: 29508751
DOI: 10.1016/S1470-2045(18)30071-8

No abstract available

PubMed Disclaimer

Comment in

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
Wu YL, Zhong WZ. Wu YL, et al. Lancet Oncol. 2018 Mar;19(3):e127. doi: 10.1016/S1470-2045(18)30133-5. Lancet Oncol. 2018. PMID: 29508752 No abstract available.

Comment on

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.

Similar articles

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
Ma JA, Jiang S, Hu C, Xie Y, Hou T. Ma JA, et al. Lancet Oncol. 2018 Mar;19(3):e125. doi: 10.1016/S1470-2045(18)30074-3. Lancet Oncol. 2018. PMID: 29508750 No abstract available.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
Wu F, Liu X, Ma JA, Gao Y, Hu C. Wu F, et al. Lancet Oncol. 2018 Mar;19(3):e124. doi: 10.1016/S1470-2045(18)30073-1. Lancet Oncol. 2018. PMID: 29508749 No abstract available.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
Wu YL, Zhong WZ. Wu YL, et al. Lancet Oncol. 2018 Mar;19(3):e127. doi: 10.1016/S1470-2045(18)30133-5. Lancet Oncol. 2018. PMID: 29508752 No abstract available.
Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.
Viallet J, Ayoub J, Rousseau P, Souhami L, Hohneker J, Shepherd F. Viallet J, et al. Semin Oncol. 1994 Oct;21(5 Suppl 10):64-71; discussion 71-2. Semin Oncol. 1994. PMID: 7973771 Review.
Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
Sasidharan R, Gibbs D, Sullivan R, Simpson A, Perez D, Christmas T, McKeage M. Sasidharan R, et al. N Z Med J. 2006 Nov 17;119(1245):U2310. N Z Med J. 2006. PMID: 17146485 Review.

See all similar articles

Cited by

Silencing LMNB1 Contributes to the Suppression of Lung Adenocarcinoma Development.
Tang D, Luo H, Xie A, He Z, Zou B, Xu F, Zhang W, Xu X. Tang D, et al. Cancer Manag Res. 2021 Mar 18;13:2633-2642. doi: 10.2147/CMAR.S275874. eCollection 2021. Cancer Manag Res. 2021. PMID: 33776481 Free PMC article.
ZNF280A promotes lung adenocarcinoma development by regulating the expression of EIF3C.
Liu H, Qin Y, Zhou N, Ma D, Wang Y. Liu H, et al. Cell Death Dis. 2021 Jan 4;12(1):39. doi: 10.1038/s41419-020-03309-9. Cell Death Dis. 2021. PMID: 33414445 Free PMC article.
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.
Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. Karachaliou N, et al. Transl Cancer Res. 2019 Jan;8(Suppl 1):S23-S47. doi: 10.21037/tcr.2018.10.06. Transl Cancer Res. 2019. PMID: 35117062 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal